Business Description
AB Science
ISIN : FR0010557264
Total Employee Number:
36Compare
Compare
Traded in other countries / regions
AB.France0Q77.UKA8D.GermanyABSCF.USA IPO Date
2011-01-05Description
AB Science is a clinical-stage pharmaceutical company that has developed a diversified portfolio of medicines targeting unmet medical needs, based on two platforms. Masitinib platform: It is based on masitinib, a selective protein kinase inhibitor in development for neurodegenerative diseases, oncology, & inflammatory diseases. It has the clinical development of masitinib in neurodegenerative diseases (specifically Alzheimer's disease, amyotrophic lateral sclerosis, & progressive forms of multiple sclerosis). ALDH/Microtubule Platform: It is a portfolio of synthetic agents that target cancer cells by destabilising microtubules, which are essential for cell division & cancer stem cells, by inhibiting enzymes that are essential for maintaining their physiological state & survival.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.54 | |||||
Equity-to-Asset | -0.7 | |||||
Debt-to-Equity | -1.1 | |||||
Debt-to-EBITDA | 9.78 | |||||
Interest Coverage | 0.2 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 1.12 | |||||
Beneish M-Score | 14.43 | |||||
WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 8.2 | |||||
3-Year EPS without NRI Growth Rate | 51.1 | |||||
3-Year FCF Growth Rate | 36.1 | |||||
3-Year Book Growth Rate | 30.2 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 11.09 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
14-Day RSI | 0.09 | |||||
3-1 Month Momentum % | -22.76 | |||||
6-1 Month Momentum % | -22.76 | |||||
12-1 Month Momentum % | -11.11 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.96 | |||||
Quick Ratio | 0.95 | |||||
Cash Ratio | 0.69 | |||||
Days Inventory | 226.57 | |||||
Days Sales Outstanding | 68.92 | |||||
Days Payable | 10917.72 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -12.3 | |||||
Shareholder Yield % | -14.59 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 83.31 | |||||
Operating Margin % | 54.43 | |||||
Net Margin % | -132.62 | |||||
EBITDA Margin % | 165.42 | |||||
FCF Margin % | -386.31 | |||||
OCF Margin % | -362.37 | |||||
ROA % | -6.78 | |||||
ROIC % | 3.1 | |||||
3-Year ROIIC % | 7782.63 | |||||
ROC (Joel Greenblatt) % | 167.78 | |||||
ROCE % | 32.78 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 46 | |||||
EV-to-EBIT | 41.79 | |||||
EV-to-EBITDA | 35.94 | |||||
EV-to-Revenue | 59.45 | |||||
EV-to-Forward-Revenue | 59.56 | |||||
EV-to-FCF | -15.27 | |||||
Price-to-GF-Value | 0.6 | |||||
Price-to-Median-PS-Value | 0.23 | |||||
Earnings Yield (Greenblatt) % | 2.39 | |||||
FCF Yield % | -7.5 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:ABSCF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
AB Science Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1.366 | ||
| EPS (TTM) ($) | -0.034 | ||
| Beta | -0.9714 | ||
| 3-Year Sharpe Ratio | -0.67 | ||
| 3-Year Sortino Ratio | -0.86 | ||
| Volatility % | 24.68 | ||
| 14-Day RSI | 0.09 | ||
| 14-Day ATR ($) | 0.001078 | ||
| 20-Day SMA ($) | 1.12 | ||
| 12-1 Month Momentum % | -11.11 | ||
| 52-Week Range ($) | 1.12 - 1.45 | ||
| Shares Outstanding (Mil) | 69.78 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
AB Science Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
AB Science Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Second quarter earnings results for 2026 | 2026-09-30 | In 91 days | ||
| General meeting for 2025 | 2026-06-30 16:00 | 1.12 (+0.00%) | ||
| Annual report for 2025 | 2026-05-20 | 1.12 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-05-19 | 1.12 (+0.00%) | ||
| AB Science - Update on the Phase 1 study with AB8939 | 2025-10-16 14:00 | 1.26 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-09-30 | 1.26 (+0.00%) | ||
| General meeting for 2024 | 2025-06-30 16:00 | 1.26 (+0.00%) | ||
| Annual report for 2024 | 2025-05-13 | 1.60 (+0.00%) | ||
| Fourth quarter earnings results for 2024 | 2025-05-12 | 1.60 (+0.00%) | ||
| AB Science - Live Webcast | 2025-01-28 11:30 | 0.90 (+0.00%) |
Show
Entries
AB Science Frequently Asked Questions
What is AB Science(ABSCF)'s stock price today?
The current price of ABSCF is $1.12. The 52 week high of ABSCF is $1.45 and 52 week low is $1.12.
When is next earnings date of AB Science(ABSCF)?
The next earnings date of AB Science(ABSCF) is 2026-09-30 Est..
Does AB Science(ABSCF) pay dividends? If so, how much?
AB Science(ABSCF) does not pay dividend.
Guru Commentaries on OTCPK:ABSCF
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on AB Science
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers